Table 6. Treatment-related adverse events of the 40 patients with unresectable hepatocellular carcinoma receiving lenvatinib after failure of sorafenib.

	All patients (N = 40)			Second line (N = 20)			Third line (N = 10)			Fourth and later line (N = 10)
Adverse event	Any grades	Grade 3/4		Any grades	Grade 3/4		Any grades	Grade 3/4		Any grades	Grade 3/4
Hypertension	19 (47.5%)	5 (12.5%)		9 (45.0%)	3 (15.0%)		6 (60.0%)	1 (10.0%)		4 (40.0%)	1 (10.0%)
Diarrhea	14 (35.0%)	1 (2.5%)		6 (30.0%)	0 (0%)		4 (40.0%)	1 (10.0%)		4 (40.0%)	0 (0%)
Decreased appetite	9 (22.5%)	1 (2.5%)		4 (20.0%)	1 (5.0%)		3 (30.0%)	0 (0%)		2 (20.0%)	0 (0%)
Decreased body weight	7 (17.5%)	0 (0%)		4 (20.0%)	0 (0%)		1 (10.0%)	0 (0%)		2 (20.0%)	0 (0%)
Fatigue	11 (27.5%)	1 (2.5%)		7 (35.0%)	1 (5.0%)		2 (20.0%)	0 (0%)		2 (20.0%)	0 (0%)
Palmar-plantar erythrodysesthesia	8 (20.0%)	0 (0%)		3 (15.0%)	0 (0%)		3 (30.0%)	0 (0%)		2 (20.0%)	0 (0%)
Nausea	6 (15.0%)	0 (0%)		3 (15.0%)	0 (0%)		2 (20.0%)	0 (0%)		1 (10.0%)	0 (0%)
Vomiting	2 (5.0%)	0 (0%)		1 (5.0%)	0 (0%)		1 (10.0%)	0 (0%)		0 (0%)	0 (0%)
Skin rash	3 (7.5%)	0 (0%)		1 (5.0%)	0 (0%)		1 (10.0%)	0 (0%)		1 (10.0%)	0 (0%)